Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) reached a new 52-week low on Monday. The company traded as low as $33.08 and last traded at $33.08, with a volume of 358 shares changing hands. The stock had previously closed at $33.88.
Wall Street Analyst Weigh In
Several brokerages recently issued reports on ZLDPF. Zacks Research raised Zealand Pharma A/S from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 12th. Jefferies Financial Group cut Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. Barclays downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 8th. Finally, Wells Fargo & Company reaffirmed an “overweight” rating on shares of Zealand Pharma A/S in a research note on Thursday, August 13th. Two research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and eight have given a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold”.
Check Out Our Latest Research Report on Zealand Pharma A/S
Zealand Pharma A/S Trading Down 2.4%
The company has a debt-to-equity ratio of 0.02, a current ratio of 13.98 and a quick ratio of 13.98. The firm has a market cap of $2.37 billion, a price-to-earnings ratio of 5.49 and a beta of 0.95. The firm’s fifty day moving average is $42.68 and its 200-day moving average is $45.52.
Zealand Pharma A/S Company Profile
Zealand Pharma A/S is a Denmark-based biotechnology company focused on discovering, developing and commercializing peptide-based medicines. Its research is primarily directed toward metabolic and gastrointestinal diseases, including obesity, diabetes and rare disorders. The company develops therapies designed to address significant unmet medical needs, often using innovative peptide structures and delivery approaches.
Zealand’s portfolio has included dasiglucagon, a glucagon analogue developed for the treatment of severe hypoglycemia.
Read More
- Five stocks we like better than Zealand Pharma A/S
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
- Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts
Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.
